Search

尹思哲

✎ Just do it ✎

Tag

biotech

HK-listed Lee’s Pharmaceutical unit nets $145m co-led by Hillhouse, TPG Asia

Zhaoke Ophthalmology Pharmaceutical (ZKO), an indirect subsidiary of Hong Kong-listed Lee’s Pharmaceutical Holdings Limited, has garnered as much as $145 million in its Series B round co-led by Hillhouse Capital’s Hillhouse COFL and TPG Asia, per a filing with the Stock Exchange of Hong Kong (HK

Read more: https://bit.ly/3dAE3CY

港生科股融資 10年內有力冠全球 引入兩年共籌940億

李小加認為,中國面對人口老化與醫療成本上漲,需透過生科企業尋找解決方法。(信報資料圖片)

Read more: https://bit.ly/3i6eDP0

理大獲批 270 萬研手提檢測儀及試劑 金納米粒子恆溫快速檢測助分流

要有效對應疫情,進行病毒檢測可說是重要的一環。一直以來檢測成本貴而且需時,最近理大得到政府撥款$1,800 萬,針對今次疫情作研究,當中得到超過$270 萬資助的項目是開發手提檢測儀及病毒測試劑,加快檢測流程並降低門

Read more: https://bit.ly/3gkcg9W

Professor Kelvin Kam-fai Tsoi

Professor Kelvin Tsoi is an Epidemiologist specialized in Digital Health.

Read more: https://bit.ly/2YHh3fU

Taiwanese AI healthtech startup bags $2.7m in Asus-led round

Taiwan’s Deep01, a startup that provides AI-based healthcare solutions such as medical imaging, said it has raised US$2.7 million in a round led by global electronics manufacturer AsusTeK.

Read more: https://bit.ly/2Vq34cu

A storied Chinese pharma partner of Bristol Myers, Amgen — and avid biotech supporter — plots HK IPO

Sim­cere isn’t one of the group of pre-rev­enue biotechs tak­ing ad­van­tage of Hong Kong’s 2-year-old new rules that opened up the stock ex­change.

Read more: https://bit.ly/37q4NmO

科大研電子仿生眼 感光快過人

研究團隊以氧化鋁製成半球狀薄膜,上面填滿由鈣鈦礦納米電線,作用類似人眼感光細胞。(Nature網上圖片)

Read more: https://bit.ly/2XqrGlf

抗疫期間見真章 香港生物科技有人才有市場

香港屢屢被評缺乏科研,就連中大前校長沈祖堯都曾指因港府資金少令研究無以為繼,但其實香港的生物科技水平甚高,研發成果甚至成功衝出香港打入東南亞市場。香港人對生物科技可能認識有限,不過一提到現時的疫情,相

Read more: https://bit.ly/36o82dZ

阿里半億注資環保材料初創

寰科創新研發的綠色複合材料,可用來製作餐具。圖為寰科創新創辦人兼行政總裁陳大仁。(香港科技園提供)

Read more: https://bit.ly/2LAy1VU

AI in medicine might be overhyped

Read more: https://bit.ly/2QQNfJk

Co-working lab and office for biotech startups opens in Singapore

Singapore-based NSG BioLabs, a new incubator for biotech startups, has officially launched today, setting up the first co-working laboratory and office space in the city-state’s research and development hub for biomedical sciences.

Read more: http://bit.ly/2rMwW6z

Alibaba fund to boost investments in Hong Kong biotech firms

Alibaba Hong Kong Entrepreneurs Fund, the US$131 million venture capital fund started by Jack Ma, plans to boost investments in Hong Kong’s biotech startups that could become the next unicorn, expanding its focus from fintech and AI.

Read more: http://bit.ly/2Q4r0zX

Why Hong Kong’s bet on biotech is doomed to fail – if private backers don’t step up

Hong Kong is betting on biotechnology for the future as mapped out in the recent Budget but private sector investments are so anaemic that the few players around fear the industry may never take off in the city.

Read more: http://bit.ly/2yvGm6T

Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag, a Thrombopoietin Receptor Agonist

OSAKA, Japan, /PRNewswire/ — Shionogi & Co., Ltd. (hereafter “Shionogi” or “the Company”) announces that the Company has concluded an agreement with Eddingpharm (hereafter “Eddingpharm”) to license-out lusutrombopag, a thrombopoietin receptor agonist (brand name in Japan: MULPLETA®).

Read more: https://prn.to/2XONsh1

Live Long And Prosper: How Anne Wojcicki’s 23andMe Will Mine Its Giant DNA Database For Health And Wealth

Anne Wojcicki is 45 minutes late, something so encoded in her habits as 23andMe’s CEO that employees have stopped complaining about it. They know it’s hardwired.

Read more: http://bit.ly/2Y3y6sW

Sophia Genetics bags $77M Series E, with 850+ hospitals signed up to its ‘data-driven medicine’

Another sizeable cash injection for big data biotech: Sophia Genetics has announced a $77 million Series E funding round, bringing its total raised to $140 million since the business was founded back in 2011.

Read more: https://tcrn.ch/2XMmG8Y

啟動生物科技引擎 創科激發營商潛力

一直以來,香港擁有堅實的科技基礎及雄厚的科研實力,更是亞洲頂尖學府、各類研究機構及高水準的專業人員的熔爐。加上,擁有基建配套齊備及政策完善,如低稅政策等先天優勢,孕育出發展蓬勃的生物科技企業生態系統,

Read more: http://bit.ly/2Y3sTS0

Cancer sucks, but there are some exciting developments on the research front. In the last month alone, we’ve seen regulators consider a CRISPR therapy that directly targets tumor cells—a first for the U.S.

Read more: http://bit.ly/2RereTX

【人造肉熱潮】Beyond Meat股價爆升 雀巢火速應戰推人造肉

人造肉第一股Beyond Meat於美股上市僅1個月,股價爆升3倍,帶起人造肉熱潮。就連全球最大的食品企業雀巢亦不甘後人,馬上加入人造肉的戰綫,將於今年秋季於美國推出人造肉應市。

Read more: http://bit.ly/2XrVVXN

【李嘉誠有份】維港投資旗下益生菌產品登陸香港 將領導最新一輪融資

李嘉誠有份投資的嬰兒益生菌生產商Evolve BioSystems,宣佈旗艦產品Evivo透過Evivo.

Read more: http://bit.ly/2wxZeRy

Impossible Foods再獲23億融資 用於增加產能

科技素食成為市場新焦點。李嘉誠有份投資的初創公司Impossible Foods宣布最新獲得E輪股權融資注入3億美元(約23億港元)資金,這次E輪融資由現有投資者淡馬錫(Temasek)及李嘉誠旗下的維港投資帶領進行。整輪E輪融資總金額已

Read more: http://bit.ly/2XqsiWR

生科股熱潮退 融資趨難 業界:中資企業最受影響 估值料受壓

明報記者 陳惠恩 內地去年限制走資,影響上市公司的估值水平,生物科技股亦同受影響。夏爾巴投資創始人及管理合伙人蔡大慶表示,目前資金流向稍為偏穩,但市場仍盼望有較明顯的放開資金限制。他認為,估值對生物科技

Read more: http://bit.ly/2wzXibn

生科企港IPO今明年料回勇

原文刊於信報財經新聞 港交所(00388)改革上市規則,准許無收入生物科技公司上市至今約1年,華興資本(01911)董事總經理兼醫療與生命科技事業部負責人謝屹璟預期,今明兩年將有更多中外生科企業來港上市,定價亦會隨

Read more: http://bit.ly/2Xb6aja

Evolve獲維港及蓋茨基金投資 美嬰兒益生菌製劑攻港

原文刊於信報財經新聞專欄「StartupBeat創科鬥室」 Evivo入門套裝足夠嬰兒服用4周,售價由638港元起。(Evivo網上圖片) 美國生物科技公司Evolve BioSystems周一(6日)宣布,在香港和新加坡等市場,推出其嬰幼兒益生菌產品Evivo。

Read more: http://bit.ly/2YJPlfR

21家生物医药企业“抢滩”科创板,一级市场的喜与忧

功能介绍 最新鲜犀利的商业见闻,最国际视野的前沿技术,最不常见的独家猛料。钛媒体(www.tmtpost.

Read more: http://bit.ly/2VgpO0p

Biotech start-up backed by Li Ka-shing and Bill Gates to launch its immunity-boosting gut bacteria in Hong Kong, Singapore

Evolve BioSystems’ dietary supplement works by reintroducing a beneficial gut bacteria that is missing in today’s babies

Read more: http://bit.ly/2J4Af0l

Scientists print first 3D heart using a patient’s own cells

Researchers at Tel Aviv University managed to successfully print the first ever 3D heart that uses cells and biological materials from a patient.

Read more: https://engt.co/2GoJp5g

38 万,克隆一只宠物

从母体取下的细胞停止衰老;狗的某个基因可以被人为编辑或去除;死去的宠物可以重生;两条外表和遗传基因完全一致的狗在一起嬉闹……

Read more: http://bit.ly/2UXh0eF

23andMe獲核准,可透過基因檢測提供客戶帕金森氏症等10種疾病風險資訊

兩週前,美國食藥署(FDA)公布23andME可以透過基因檢測提供客戶關於10種疾病的資訊。23andMe是一家基因科技公司,創辦於2006年,位於加州透過受試者唾液取得去氧核醣核酸(DNA)以進行個人化基因檢測的公司,募資超過2.

Read more: http://bit.ly/2Dzsavy

Read more: https://econ.st/2wRzEIG

Create a website or blog at WordPress.com

Up ↑